跳至主要内容
临床试验/CTRI/2022/12/048082
CTRI/2022/12/048082尚未招募3 期

Comparative study of 0.5% Ropivacaine plus magnesium sulfate versus 0.5% Ropivacaine plus Dexmedetomidine as an adjuvant in brachial plexus block

Subhashree Sahu1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2022年12月15日最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
60
试验地点
1
主要终点
Dexmedetomidine provide longer duration of analgesia than magnesium sulfate

研究概览

简要总结

60 patients will be divided into two groups.1 group will receive inj Ropivacaine 0.5% plus inj Dexmedetomidine 0.7mcg/kg and another group will receive inj Ropivacaine 0.5% plus inj magnesium sulfate 4mg/kg..VAS score will be measured at 0hr, 1hr,2hr,4hr,6hr,12hr,24hr

研究设计

研究类型
Interventional
分配方式
Computer generated randomization
盲法
Participant Blinded

入排标准

年龄范围
18.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • Patients with forearm fracture of ASA PS-I, II, WEIGHT -40Kg to 70 kg to be included in the study.

排除标准

  • Patient refusal, infection at the site of block, known allergy to the drugs uesd in the study, patients with coagulation disorder.

结局指标

主要结局

Dexmedetomidine provide longer duration of analgesia than magnesium sulfate

时间窗: VAS SCORE will be assessed at base line, 1hr,2hr,4hr,8hr,12hr,18hr,24hr

次要结局

  • Total Rescue analgesia requirement will be less in Dexmedetomidine group than magnesium sulfate group(VAS SCORE at 0hr, 1hr,2hr,4hr,6hr,12hr,24hr to be measured.)

研究者

发起方
Subhashree Sahu
申办方类型
Other [self]

研究点 (1)

Loading locations...

相似试验